c-Kit (D816H)

KIT · Variant type: point · HGVS: p.D816H

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Avapritinib	99.1%	0.9%	97.73
2	Nintedanib	98.9%	1.1%	90.23
3	Dasatinib	98.9%	1.1%	87.97
4	Ripretinib	98.3%	1.7%	92.95
5	Tivozanib	97.7%	2.3%	92.42
6	Brigatinib	97.3%	2.7%	82.96
7	Ponatinib	96.9%	3.1%	78.23
8	Selpercatinib	96.8%	3.2%	96.72
9	Pacritinib	95.1%	4.9%	88.64
10	Pralsetinib	93.7%	6.3%	93.43
11	Bosutinib	92.7%	7.3%	87.22
12	Gilteritinib	92.1%	7.9%	88.97
13	Erdafitinib	89.2%	10.8%	95.71
14	Fostamatinib	87.5%	12.5%	96.74
15	Sunitinib	86.4%	13.6%	91.73
16	Mitapivat	79.3%	20.7%	100.00
17	Capivasertib	79.2%	20.8%	96.48
18	Vandetanib	76.7%	23.3%	95.74
19	Apatinib	74.0%	26.0%	97.73
20	Alectinib	71.5%	28.6%	95.49
21	Umbralisib	65.4%	34.6%	98.74
22	Sorafenib	64.5%	35.5%	96.72
23	Pazopanib	61.6%	38.4%	97.49
24	Fedratinib	61.1%	38.9%	96.21
25	Regorafenib	57.2%	42.8%	95.99

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Avapritinib	99.1%	—	—
Nintedanib	98.9%	—	—
Dasatinib	98.9%	—	—
Ripretinib	98.3%	—	—
Tivozanib	97.7%	—	—
Brigatinib	97.3%	—	—
Ponatinib	96.9%	—	—
Selpercatinib	96.8%	—	—
Pacritinib	95.1%	—	—
Pralsetinib	93.7%	—	—
Bosutinib	92.7%	—	—
Gilteritinib	92.1%	—	—
Erdafitinib	89.2%	—	—
Fostamatinib	87.5%	—	—
Sunitinib	86.4%	—	—
Mitapivat	79.3%	—	—
Capivasertib	79.2%	—	—
Vandetanib	76.7%	—	—
Apatinib	74.0%	—	—
Alectinib	71.5%	—	—
Umbralisib	65.4%	—	—
Sorafenib	64.5%	—	—
Pazopanib	61.6%	—	—
Fedratinib	61.1%	—	—
Regorafenib	57.2%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 40.6ms